IP Library Granted Patent US 11,759,499
Granted Patent B2
US 11,759,499 · App. 17/235,653 · Granted Sep 19, 2023

Compositions and methods for prevention and treatment of corneal haze and scarring

Inventors: Sunil Chauhan (Cambridge, MA); Reza Dana (Newton, MA)
Assignee: The Schepens Eye Research Institute, Inc.
A61K38/1833A61K9/0048A61P27/02C07K14/00C07K14/4753
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,759,499
App. No.
17/235,653
Granted
Sep 19, 2023
Kind
B2
Abstract

This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.

Claims (10)

1. A method of treating corneal haze or scarring comprising administering a composition comprising purified hepatocyte growth factor (HGF) polypeptide, wherein the HGF polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1, to a subject in need thereof, where the composition is topically administered to the cornea and the corneal haze or scarring is reduced in severity.

2. The method of claim 1 wherein the HGF polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 1.

3. The method of claim 1 wherein the HGF polypeptide comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 1.

4. The method of claim 1 , wherein the purified HGF agent is present in a concentration of 0.001% to 1% w/v.

5. The method of claim 1 , wherein the HGF polypeptide is present in a concentration of about 0.005% to 0.5% w/v.

6. The method of claim 1 , wherein the HGF polypeptide is present in a concentration of about 0.01% w/v.

7. The method of claim 1 , wherein the composition is administered daily for 5 days after an injury to the cornea.

8. The method of claim 1 , wherein the composition is administered daily for 3 days after an injury to the cornea.

9. The method of claim 1 , wherein the composition is administered 1 day after an injury to the cornea.

10. The method of claim 1 , wherein the composition is formulated as an eye drop.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2025
From: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 070593/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2022
From: CHAUHAN, SUNIL; DANA, REZA
To: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
Reel/Frame 059109/0883 →
Continuity (4)
Continuation 16657913 · Oct 18, 2019
Continuation 15759203
Provisional Application 62217611 · Sep 11, 2015
Related Publication 20210299219A1 · Sep 30, 2021